While waiting in a big Manhattan hospital about 15 years ago, I glimpsed the chairman of one of the world’s biggest banks in a consulting room. I never found out why he was there. If he was ill, his employer never said and the man is now enjoying a long and apparently healthy retirement.
The Innovator’s Dilemma was published in 1997, so when The New Yorker last week printed a detailed dissection of disruptive innovation, the idea at the heart of Clayton Christensen’s book, my first reaction was: what took critics so long?
Clayton Christensen (Peter Foley/Bloomberg)
Clay Christensen is a gentle man, of devout Mormon faith, prone to sentimentality and beloved by many – not least for his lessons to students on how to find fulfilment, which he turned into an unexpected bestseller, How Will You Measure Your Life?
But the avuncular Harvard Business School star is hot under the collar about this week’s New Yorker attack on the book (The Innovator’s Dilemma) and theory (disruptive innovation) for which he is best known.
What seems to have made him particularly angry is the fact that the author, Jill Lepore, who is also a Harvard academic, did not drop by to chat to him about her detailed allegations that his theory does not stand up. Read more
I met Carey Eaton only once, at a conference five weeks ago in Switzerland, far from Kenya, where he grew up, lived and built a thriving internet business. He was engaging, upbeat and generous with his time and knowledge.
Clayton Christensen: straight talking on complex ideas about innovation Photo: Bloomberg
And still they come. The stream of articles, books and research purporting to tell people how to innovate is unending. But is there anything new in innovation?
A lot of what is sold as new thinking is actually “people applying their own language to something that isn’t really different from what has been applied before”. That is the view of Scott Anthony, a Singapore-based partner at Innosight, the consultancy co-founded by Clayton Christensen – an acknowledged master of using straightforward language to help business people understand complex ideas on innovation. Read more
We have been presented this week with two visions for the future of innovation in the pharmaceuticals industry. One is encouraging, the other is not.
You would be quite happy to allow someone else to open the boot of your car and drop off your groceries while you are absent. You would trust random strangers to deliver your new shoes on their way past your home. You would gladly accept a prescription-drug order from an unidentified flying object hovering outside your door. All to avoid going the extra mile to pick up cheap goods ordered online in person.
Bitcoin is being forced to grow up fast. The arrest last week on money laundering charges of Charlie Shrem, a leading Bitcoin champion, coincided with a regulatory hearing in New York to consider what on earth it is – a virtual currency, speculative asset or a means of exchange?